Format

Send to

Choose Destination
Br J Haematol. 2008 Nov;143(4):455-67. doi: 10.1111/j.1365-2141.2008.07295.x. Epub 2008 Sep 10.

The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Author information

1
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, School of Medicine, University of Washington, Seattle, WA, USA. mboeckh@fhcrc.org

Abstract

Respiratory virus infections in hematopoietic cell transplant (HCT) recipients are a major cause of morbidity and mortality. While respiratory syncytial virus (RSV), human metapneumovirus, parainfluenzaviruses, and influenza viruses are well known for their potential to cause fatal pneumonia, information has only recently emerged regarding the significance of the newly discovered viruses, such as human coronaviruses NL63 and HKU1, and human bocavirus. Lymphopenia seems to be the most important risk factor for progression to lower respiratory tract disease. Airflow obstruction is another complication of respiratory virus infections after HCT, and data to date indicate this complication may occur following parainfluenza virus and RSV infection. Infection control procedures are key for prevention. Unfortunately, there are no randomized treatment studies, which make the interpretation of the literature on interventions difficult. This article reviews the spectrum of pathogens, epidemiology, risk factors and clinical manifestations of infection, as well as recent advances in diagnostic and clinical management.

PMID:
18785968
PMCID:
PMC2735199
DOI:
10.1111/j.1365-2141.2008.07295.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center